Jiayuan Sun
12
1
1
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
The Percutaneous Interventional Surgery Control System for Pulmonary Nodule Biopsy
Role: lead
Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
Role: lead
Hybrid APC Therapy in Early Central Lung Neoplasms
Role: lead
Feasibility Study of the Pulsed Electric Field Ablation System in Treating Chronic Bronchitis
Role: lead
22G-ProCore vs 22G-Standard Needle in Diagnosis of Lymphadenopathy by EBUS-TBNA
Role: lead
Methylation of cfDNA in Diagnosing and Monitoring Pulmonary Nodule
Role: lead
VBN-EBUS-GS-TBLB With or Without Fluoroscopy for the Diagnosis of PPLs
Role: lead
Bronchoscopy Screening for High-risk Population of Lung Cancer With Severe Smoking With Negative LDCT Screen
Role: lead
Bronchoscopic ICG Injection and Percutaneous Hook-wire Techniques for Preoperative Lung Nodule Localization in VATS
Role: lead
EBUS-TBNA-RTE VS Radiography in Staging of NSCLC
Role: lead
Mutation Detection of EBUS-TBNA Specimens Using NGS
Role: lead
Comparison of Gene Mutations in Matched Samples in Advanced Nonsquamous NSCLC Using NGS
Role: lead
All 12 trials loaded